Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $30.4 million.

  • Xeris Biopharma Holdings' Accumulated Expenses rose 28.91% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year increase of 28.91%. This contributed to the annual value of $27.7 million for FY2024, which is 17.89% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Accumulated Expenses of $30.4 million as of Q3 2025, which was up 21.55% from $25.0 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Accumulated Expenses peaked at $49.1 million during Q4 2021, and registered a low of $19.1 million during Q3 2023.
  • Over the past 3 years, Xeris Biopharma Holdings' median Accumulated Expenses value was $23.5 million (recorded in 2024), while the average stood at $23.2 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Accumulated Expenses soared by 208.83% in 2021 and then tumbled by 49.42% in 2023.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Accumulated Expenses stood at $49.1 million in 2021, then dropped by 25.06% to $36.8 million in 2022, then tumbled by 36.09% to $23.5 million in 2023, then rose by 17.89% to $27.7 million in 2024, then increased by 28.91% to $30.4 million in 2025.
  • Its last three reported values are $30.4 million in Q3 2025, $25.0 million for Q2 2025, and $20.1 million during Q1 2025.